3 Reasons Wall Street Thinks InMode Can Rocket 47% Higher in 2023
Individual investors who want help picking stocks have more than a few options to choose from, including the recommendations of Wall Street analysts.
Right now, InMode (NASDAQ: INMD) is a medical technology stock that analysts on Wall Street can't seem to get enough of. Among those who follow InMode, the average analyst is targeting a 47% gain for the stock over the next year.
Analysts usually have considerably more resources to work with than the average retail investor. That said, you shouldn't choose stocks for your portfolio based entirely on their eye-popping price targets. Let's examine three of the reasons analysts are pounding the table for InM0ode stock to see if it deserves a spot in your portfolio.
Source Fool.com